KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2026)

Pacific Biosciences Of California has reported Convertible Debt over the past 5 years, most recently at $645.4 million for Q4 2025.

  • For Q4 2025, Convertible Debt changed 0.33% year-over-year to $645.4 million; the TTM value through Dec 2025 reached $645.4 million, changed 0.33%, while the annual FY2025 figure was $645.4 million, 0.33% changed from the prior year.
  • Convertible Debt for Q4 2025 was $645.4 million at Pacific Biosciences Of California, roughly flat from $645.2 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $896.8 million in Q1 2023 and troughed at $645.2 million in Q3 2025.
  • A 5-year average of $829.2 million and a median of $892.8 million in 2024 define the central range for Convertible Debt.
  • Biggest five-year swings in Convertible Debt: rose 0.13% in 2024 and later dropped 27.77% in 2025.
  • Year by year, Convertible Debt stood at $896.1 million in 2021, then rose by 0.07% to $896.7 million in 2022, then decreased by 0.5% to $892.2 million in 2023, then decreased by 27.43% to $647.5 million in 2024, then fell by 0.33% to $645.4 million in 2025.
  • Business Quant data shows Convertible Debt for PACB at $645.4 million in Q4 2025, $645.2 million in Q3 2025, and $646.4 million in Q2 2025.